JP7111795B2 - 組合せhiv治療薬 - Google Patents
組合せhiv治療薬 Download PDFInfo
- Publication number
- JP7111795B2 JP7111795B2 JP2020212055A JP2020212055A JP7111795B2 JP 7111795 B2 JP7111795 B2 JP 7111795B2 JP 2020212055 A JP2020212055 A JP 2020212055A JP 2020212055 A JP2020212055 A JP 2020212055A JP 7111795 B2 JP7111795 B2 JP 7111795B2
- Authority
- JP
- Japan
- Prior art keywords
- nanosomes
- making
- phospholipids
- latent viral
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本出願は、2015年5月22日出願の米国特許仮出願第62/165444号の優先権を主張するものであり、前記仮出願はこの全体が参照により本明細書に組み込まれる。
本発明の実施形態は、連邦政府の基金または支援を得て考案または実行されたものではない。
Claims (13)
- 潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法であって、前記ナノソームは、親水性物質およびHDAC阻害剤の混合物を有する水性コア、リン脂質およびブリオイドの混合物を有する周囲を取り囲む層、ならびに外表面を有し、前記周囲を取り囲む層が前記コアを包み込み、前記外表面が前記周囲を取り囲む層を取り囲み、
超臨界流体、臨界流体、または近臨界流体中のリン脂質物質供給源を提供する工程と、
アルコール溶液中のブリオイド供給源を提供する工程と、
前記リン脂質の液体および前記ブリオイドの溶液の混合物を形成する工程と、
背圧調整装置を使用して前記混合物を減圧する工程と、
前記混合物を、注入ノズルを通して、親水性水溶液中のHDAC阻害剤を含む減圧容器に流れとして注入する工程と
を含み、気泡が、前記注入ノズルで形成され、前記ノズルから離れ、壊れて、リン脂質の二重層を剥離させ、これによって前記HDAC阻害剤および前記ブリオイドを封入し、自発的に密封して、前記ナノソームを形成する、方法。 - 前記HDAC阻害剤が、アルコール溶液中にある、請求項1に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製するための方法。
- 前記ブリオイド供給源が、緩衝液中に含まれる、請求項1に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製するための方法。
- 前記ブリオイドが、ブリオスタチン1から20および他の公知のブリオスタチンまたは同定されたブリオスタチンからなるブリオスタチンからなる群から選択される、請求項1に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法。
- 前記HDAC阻害剤が、バルプロ酸、ボリノスタット、ロミデプシン、およびパノビノスタットからなる群から選択される、請求項1に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法。
- 前記リン脂質物質供給源が、超臨界流体、臨界流体、または近臨界流体中にリン脂質溶液を形成するための固体チャンバー、混合チャンバー、および循環ループに含まれる、請求項1に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法。
- 前記潜在性ウイルス疾患の処置に有効な抗体を前記ナノソームの前記外表面における前記リン脂質の親水性頭部と会合させて、前記ナノソームの前記外表面を前記抗体で被覆する工程をさらに含む、請求項1に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法。
- 前記潜伏性ウイルス疾患に関連するウイルスがウイルス成分を有し、前記ウイルス成分に特異的な1つ以上のリガンドを前記ナノソームの前記外表面における前記リン脂質の親水性頭部と会合させて、前記ナノソームの外表面を前記リガンドで被覆する工程をさらに含む、請求項1に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法。
- 前記被覆工程が、CD-4細胞を上方調節するために、1つ以上の上方調節リガンドを前記ナノソームの前記外表面における前記リン脂質の親水性頭部と会合させて、前記上方調節リガンドが前記ナノソームの前記外表面に組み入れられることを含む、請求項8に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法。
- 潜伏性ウイルス疾患の処置に使用するためのナノソームを作製するための方法であって、前記ナノソームは、親水性物質およびHDAC阻害剤の混合物を有する水性コア、リン脂質およびブリオイドの混合物を有する周囲を取り囲む層、ならびに外表面を有し、前記周囲を取り囲む層が前記コアを包み込み、前記外表面が前記周囲を取り囲む層を取り囲み、前記方法は、親水性物質およびHDAC阻害剤の混合物を有する水性コアを形成する工程と、リン脂質およびブリオイドの混合物を有する周囲を取り囲む層を形成する工程と、前記周囲を取り囲む層を取り囲む外表面を形成する工程とを含む、方法。
- 前記潜在性ウイルス疾患の処置に有効な抗体を前記ナノソームの前記外表面における前記リン脂質の親水性頭部と会合させて、前記ナノソームの前記外表面を前記抗体で被覆する工程をさらに含む、請求項10に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法。
- 前記潜伏性ウイルス疾患に関連するウイルスがウイルス成分を有し、前記ウイルス成分に特異的な1つ以上のリガンドを前記ナノソームの前記外表面における前記リン脂質の親水性頭部と会合させて、前記ナノソームの前記外表面を前記リガンドで被覆する工程さらに含む、請求項11に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法。
- 前記被覆工程が、CD-4細胞を上方調節するために、1つ以上の上方調節リガンドを前記ナノソームの前記外表面における前記リン脂質の親水性頭部と会合させて、前記上方調節リガンドが前記ナノソームの前記外表面に組み入れられることを含む、請求項12に記載の潜伏性ウイルス疾患の処置に使用するためのナノソームを作製する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562165444P | 2015-05-22 | 2015-05-22 | |
US62/165,444 | 2015-05-22 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017560686A Division JP6816030B2 (ja) | 2015-05-22 | 2016-05-23 | 組合せhiv治療薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021054853A JP2021054853A (ja) | 2021-04-08 |
JP7111795B2 true JP7111795B2 (ja) | 2022-08-02 |
Family
ID=57394156
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017560686A Active JP6816030B2 (ja) | 2015-05-22 | 2016-05-23 | 組合せhiv治療薬 |
JP2020212055A Active JP7111795B2 (ja) | 2015-05-22 | 2020-12-22 | 組合せhiv治療薬 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017560686A Active JP6816030B2 (ja) | 2015-05-22 | 2016-05-23 | 組合せhiv治療薬 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10493030B2 (ja) |
EP (1) | EP3297608B1 (ja) |
JP (2) | JP6816030B2 (ja) |
CN (1) | CN107708674A (ja) |
HK (1) | HK1253011A1 (ja) |
WO (1) | WO2016191363A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
JPWO2018124033A1 (ja) * | 2016-12-26 | 2019-11-14 | 富士フイルム株式会社 | 脂質粒子組成物および医薬組成物 |
US11234932B2 (en) * | 2017-11-21 | 2022-02-01 | Aphios Corporation | Combination HIV therapeutic |
US20230139328A1 (en) * | 2020-03-12 | 2023-05-04 | Aphios Corporation | Dosage forms for improving organ transplantation, graft versus host disease and stem cells transplants |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010504735A (ja) | 2006-07-13 | 2010-02-18 | インスティチュート フォー アドバンスド スタディ | ウイルス阻害性ヌクレオチド配列およびワクチン |
US20200093742A1 (en) | 2017-11-21 | 2020-03-26 | Aphios Corporation | Combination hiv therapeutic |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100316609A1 (en) * | 2006-10-18 | 2010-12-16 | University Of Rochester | Conditionally Replicating Viruses for Cancer Therapy |
AT509277A1 (de) * | 2008-03-05 | 2011-07-15 | Moeller Gebaeudeautomation Gmbh | Schaltgerät |
US20100166806A1 (en) * | 2008-12-29 | 2010-07-01 | Aphios Corporation | Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency |
US8637074B2 (en) * | 2009-03-31 | 2014-01-28 | Aphios Corporation | Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product |
ES2618380T3 (es) * | 2010-09-24 | 2017-06-21 | International Aids Vaccine Initiative | Novedosos anticuerpos con amplio poder neutralizante de VIH-1 |
US9034347B2 (en) * | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
US20150320893A1 (en) * | 2012-05-03 | 2015-11-12 | Joseph M VOLPE | Treatment of latent hiv infection |
JP6845691B2 (ja) | 2013-11-01 | 2021-03-24 | イェール ユニバーシティーYale University | 免疫療法のための調節粒子 |
-
2016
- 2016-05-23 WO PCT/US2016/033766 patent/WO2016191363A1/en active Application Filing
- 2016-05-23 CN CN201680029646.XA patent/CN107708674A/zh active Pending
- 2016-05-23 JP JP2017560686A patent/JP6816030B2/ja active Active
- 2016-05-23 EP EP16800598.1A patent/EP3297608B1/en active Active
- 2016-05-23 US US15/576,190 patent/US10493030B2/en active Active
-
2018
- 2018-09-27 HK HK18112377.8A patent/HK1253011A1/zh unknown
-
2020
- 2020-12-22 JP JP2020212055A patent/JP7111795B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010504735A (ja) | 2006-07-13 | 2010-02-18 | インスティチュート フォー アドバンスド スタディ | ウイルス阻害性ヌクレオチド配列およびワクチン |
US20200093742A1 (en) | 2017-11-21 | 2020-03-26 | Aphios Corporation | Combination hiv therapeutic |
Non-Patent Citations (1)
Title |
---|
Activation of Latent HIV Using Drug-Loaded Nanoparticles,PLOS ONE,2011年04月,Vol.6,Issue 4,pages 1-8 |
Also Published As
Publication number | Publication date |
---|---|
WO2016191363A1 (en) | 2016-12-01 |
JP6816030B2 (ja) | 2021-01-20 |
EP3297608A1 (en) | 2018-03-28 |
CN107708674A (zh) | 2018-02-16 |
EP3297608B1 (en) | 2022-07-13 |
WO2016191363A8 (en) | 2017-10-12 |
JP2021054853A (ja) | 2021-04-08 |
EP3297608A4 (en) | 2019-01-16 |
US10493030B2 (en) | 2019-12-03 |
JP2018515567A (ja) | 2018-06-14 |
US20180133155A1 (en) | 2018-05-17 |
HK1253011A1 (zh) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7111795B2 (ja) | 組合せhiv治療薬 | |
Bender et al. | Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro | |
Singh et al. | Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS | |
KR102090740B1 (ko) | 암 치료 및 식품 관련 화합물을 포함하는 의학 분야에서 양친매성 또는 소수성 분자를 위한 나노입자, 제조 방법 및 담체로의 용도 | |
Zhang et al. | Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection | |
Ripoli et al. | Phytoliposome-based silibinin delivery system as a promising strategy to prevent hepatitis C virus infection | |
Xu et al. | Cinnamon cassia oil chitosan nanoparticles: Physicochemical properties and anti-breast cancer activity | |
Faria et al. | Lipid nanocarriers for anti-HIV therapeutics: A focus on physicochemical properties and biotechnological advances | |
Zhang et al. | The current landscape of the antimicrobial peptide melittin and its therapeutic potential | |
Medvedeva et al. | Pharmacological agents and transport nanosystems based on plant phospholipids | |
Meng et al. | Pharmacologic therapies of ARDS: From natural herb to nanomedicine | |
Ren et al. | Current trends on repurposing and pharmacological enhancement of andrographolide | |
US11234932B2 (en) | Combination HIV therapeutic | |
CN114652683A (zh) | 一种Mdivi-1纳米长循环脂质体及其制备方法和应用 | |
Ling et al. | Cancer cell membrane-coated bacterial ghosts for highly efficient paclitaxel delivery against metastatic lung cancer | |
Hong et al. | Nanosome‐Mediated Delivery Of Hdac Inhibitors and Oxygen Molecules for the Transcriptional Reactivation of Latent Hiv‐Infected Cd4+ T Cells | |
Zhang et al. | Nanomedicine approaches against SARS-CoV-2 and variants | |
Li et al. | Curcumin exerts protective effect on PC12 cells against lidocaine-induced cytotoxicity by suppressing the formation of NLRP3 inflammasome. | |
Nayak et al. | Lymphatic delivery of anti-HIV drug nanoparticles | |
Chatterjee et al. | siRNA-based novel therapeutic strategies to improve effectiveness of antivirals: an insight | |
Arab et al. | Immunoregulatory effects of nanocurcumin in inflammatory milieu: Focus on COVID-19 | |
Thamrook et al. | Applications of lipid core nanocapsules: novel drug delivery system | |
RU2440128C1 (ru) | Способ комплексной патогенетической терапии острых форм вирусного гепатита в и микст-гепатитов (в+с, в+d, в+с+d) | |
Zhou et al. | Artemisinin-type drugs in tumor cell death: mechanisms, combination treatment with biologics and nanoparticle delivery. Pharmaceutics 2022; 14: 395 | |
TW201946613A (zh) | 用於治療增生性失調的劑量方案 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210120 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220617 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220712 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220721 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7111795 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |